Literature DB >> 25969470

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.

Anthony Cleare1, C M Pariante2, A H Young3, I M Anderson4, D Christmas5, P J Cowen6, C Dickens7, I N Ferrier8, J Geddes9, S Gilbody10, P M Haddad11, C Katona12, G Lewis12, A Malizia13, R H McAllister-Williams14, P Ramchandani15, J Scott16, D Taylor17, R Uher18.   

Abstract

A revision of the 2008 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken in order to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in September 2012. Key areas in treating depression were reviewed and the strength of evidence and clinical implications were considered. The guidelines were then revised after extensive feedback from participants and interested parties. A literature review is provided which identifies the quality of evidence upon which the recommendations are made. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment. Significant changes since the last guidelines were published in 2008 include the availability of new antidepressant treatment options, improved evidence supporting certain augmentation strategies (drug and non-drug), management of potential long-term side effects, updated guidance for prescribing in elderly and adolescent populations and updated guidance for optimal prescribing. Suggestions for future research priorities are also made.
© The Author(s) 2015.

Entities:  

Keywords:  Antidepressants; depression; depressive disorder; evidence-based guidelines; treatment

Mesh:

Substances:

Year:  2015        PMID: 25969470     DOI: 10.1177/0269881115581093

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  135 in total

1.  Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance-pharmacodynamic study.

Authors:  Spyridon Siafis; Georgios Papazisis
Journal:  Br J Clin Pharmacol       Date:  2018-07-28       Impact factor: 4.335

2. 

Authors:  Tyler Yan; Ran D Goldman
Journal:  Can Fam Physician       Date:  2019-08-14       Impact factor: 3.275

Review 3.  How do antidepressants work? New perspectives for refining future treatment approaches.

Authors:  Catherine J Harmer; Ronald S Duman; Philip J Cowen
Journal:  Lancet Psychiatry       Date:  2017-01-31       Impact factor: 27.083

4.  Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis.

Authors:  Sarah R Horn; Madison M Long; Benjamin W Nelson; Nicholas B Allen; Philip A Fisher; Michelle L Byrne
Journal:  Brain Behav Immun       Date:  2018-06-19       Impact factor: 7.217

5.  Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe?

Authors:  Jennifer Severe; John F Greden; Priyanka Reddy
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-04-23

6.  Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients.

Authors:  Mai Yamamoto; Maria Ines Pinto-Sanchez; Premysl Bercik; Philip Britz-McKibbin
Journal:  Metabolomics       Date:  2019-05-20       Impact factor: 4.290

Review 7.  Prescription of Valproate-Containing Medicines in Women of Childbearing Potential who have Psychiatric Disorders: Is It Worth the Risk?

Authors:  David S Baldwin; Hugo J F Amaro
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

8.  Patterns of antidepressant use during pregnancy: a nationwide population-based cohort study.

Authors:  Anne Bénard-Laribière; Elodie Pambrun; Anne-Laure Sutter-Dallay; Sophie Gautier; Caroline Hurault-Delarue; Christine Damase-Michel; Isabelle Lacroix; Bernard Bégaud; Antoine Pariente
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

9.  Novel antidepressant effects of Paeonol alleviate neuronal injury with concomitant alterations in BDNF, Rac1 and RhoA levels in chronic unpredictable mild stress rats.

Authors:  Xiu-Ling Zhu; Jing-Jing Chen; Fei Han; Chuan Pan; Ting-Ting Zhuang; Ya-Fei Cai; Ya-Ping Lu
Journal:  Psychopharmacology (Berl)       Date:  2018-05-12       Impact factor: 4.530

10.  Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care.

Authors:  Renske C Bosman; Klaas M Huijbregts; Peter Fm Verhaak; Henricus G Ruhé; Harm Wj van Marwijk; Anton Jlm van Balkom; Neeltje M Batelaan
Journal:  Br J Gen Pract       Date:  2016-08-15       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.